RXN
Undervalued by 110.5% based on the discounted cash flow analysis.
Market cap | $7.87 Billion |
---|---|
Enterprise Value | $8.73 Billion |
Dividend Yield | $0.2594 (0.4%) |
Earnings per Share | $1.26 |
Beta | 1.35 |
Outstanding Shares | 121,105,357 |
Avg 30 Day Volume | 900,348 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 50.68 |
---|---|
PEG | -476.78 |
Price to Sales | 2.07 |
Price to Book Ratio | 3.0 |
Enterprise Value to Revenue | 4.41 |
Enterprise Value to EBIT | 27.1 |
Enterprise Value to Net Income | 56 |
Total Debt to Enterprise | 0.14 |
Debt to Equity | 0.86 |
No data
No data